Growth response in Turner syndrome with recombinant human growth hormone therapy.
Ten Turner syndrome girls whose mean age was 10.9 +/- 2.7 years were treated with recombinant human growth hormone (rhGH), dose 0.6 U/kg/week. Five of them had classical 45, XO karyotype. The mean height velocity increased from 2.8 +/- 1.3 cm/year before treatment to 6.1 +/- 2.06 cm/year after treatment for a period of 1.4 years. The response of treatment correlated well with pretreatment height velocity (<3 cm/year) but not with karyotype. However, the response has been decreasing and an increased dose after the first year of treatment is recommended.
Tuchinda
C
C
Department of Pediatrics, Siriraj Hospital, Vajira Hospital, Bangkok, Thailand.
Angsusingha
K
K
Punnakanta
L
L
Likitmaskul
S
S
Wacharasindhu
S
S
Tuanakitcharu
K
K
Pitukcheewanont
P
P
D000293:Adolescent; D001827:Body Height / Q000187:drug effects; D001846:Bone Development; D002648:Child; D003000:Clonidine / Q000627:therapeutic use; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D005500:Follow-Up Studies; D006442:Glycated Hemoglobin / Q000032:analysis; D007987:Gonadotropin-Releasing Hormone; D006128:Growth; D013006:Growth Hormone / Q000097:blood / Q000627:therapeutic use*; D006801:Humans; D007621:Karyotyping; D007986:Luteinizing Hormone / Q000097:blood; D011994:Recombinant Proteins / Q000627:therapeutic use; D013960:Thyroid Function Tests; D013997:Time Factors; D014424:Turner Syndrome / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology*
D003000:Clonidine; D004958:Estradiol; D005640:Follicle Stimulating Hormone; D006442:Glycated Hemoglobin; D007987:Gonadotropin-Releasing Hormone; D013006:Growth Hormone; D007986:Luteinizing Hormone; D011994:Recombinant Proteins